STOCK TITAN

United Therapeutics (UTHR) CFO sells 10k shares and exercises 10k options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics CFO and Treasurer James Edgemond reported a combination of stock option exercises and share sales in the company’s common stock. On May 18, 2026, he exercised options for 10,000 shares at strike prices of $117.76 and $135.42 per share, then sold 10,000 shares in multiple open-market transactions at prices between approximately $562.91 and $570.18. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, and he continues to hold United Therapeutics common stock following the activity.

Positive

  • None.

Negative

  • None.
Insider EDGEMOND JAMES
Role CFO AND TREASURER
Sold 10,000 shs ($5.67M)
Type Security Shares Price Value
Exercise Stock Option 2,500 $0.00 --
Exercise Stock Option 7,500 $0.00 --
Exercise Common Stock 2,500 $135.42 $339K
Exercise Common Stock 7,500 $117.76 $883K
Sale Common Stock 200 $562.9072 $113K
Sale Common Stock 422 $564.3045 $238K
Sale Common Stock 2,131 $565.438 $1.20M
Sale Common Stock 1,796 $566.3863 $1.02M
Sale Common Stock 2,785 $568.4765 $1.58M
Sale Common Stock 1,304 $568.4301 $741K
Sale Common Stock 1,322 $569.5576 $753K
Sale Common Stock 40 $570.18 $23K
Holdings After Transaction: Stock Option — 0 shares (Direct, null); Common Stock — 21,376 shares (Direct, null)
Footnotes (1)
  1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. This transaction was executed in multiple trades at prices ranging from $562.56 to $563.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $563.93 to $564.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $564.93 to $565.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $565.96 to $566.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $567.01 to $567.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $568.01 to $569.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $569.17 to $570.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 10,000 shares Common stock sales on May 18, 2026
Options exercised 10,000 shares Stock option exercises on May 18, 2026
Sale price range $562.9072–$570.18 per share Weighted-average prices for open-market sales
Option strike price 1 $117.76 per share 7,500-share stock option exercise
Option strike price 2 $135.42 per share 2,500-share stock option exercise
Sale transaction count 8 sale entries Non-derivative open-market sales of common stock
Exercise transaction count 2 exercises Non-derivative exercises of options into common stock
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock option financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EDGEMOND JAMES

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO AND TREASURER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026M(1)2,500A$135.4221,376D
Common Stock05/18/2026M(1)7,500A$117.7628,876D
Common Stock05/18/2026S(1)200D$562.9072(2)28,676D
Common Stock05/18/2026S(1)422D$564.3045(3)28,254D
Common Stock05/18/2026S(1)2,131D$565.438(4)26,123D
Common Stock05/18/2026S(1)1,796D$566.3863(5)24,327D
Common Stock05/18/2026S(1)2,785D$568.4765(6)21,542D
Common Stock05/18/2026S(1)1,304D$568.4301(7)20,238D
Common Stock05/18/2026S(1)1,322D$569.5576(8)18,916D
Common Stock05/18/2026S(1)40D$570.1818,876D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$135.4205/18/2026M(1)2,50003/15/202303/15/2027Common Stock2,500$0.000.00D
Stock Option$117.7605/18/2026M(1)7,50003/15/202303/15/2027Common Stock7,500$0.0080,000D
Explanation of Responses:
1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
2. This transaction was executed in multiple trades at prices ranging from $562.56 to $563.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. This transaction was executed in multiple trades at prices ranging from $563.93 to $564.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This transaction was executed in multiple trades at prices ranging from $564.93 to $565.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
5. This transaction was executed in multiple trades at prices ranging from $565.96 to $566.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
6. This transaction was executed in multiple trades at prices ranging from $567.01 to $567.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
7. This transaction was executed in multiple trades at prices ranging from $568.01 to $569.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
8. This transaction was executed in multiple trades at prices ranging from $569.17 to $570.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney05/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?

He reported exercising stock options and selling common shares of United Therapeutics. On May 18, 2026, he exercised options for 10,000 shares and sold 10,000 shares in multiple open-market transactions while continuing to hold stock afterward.

How many United Therapeutics (UTHR) shares did the CFO sell, and at what prices?

He sold a total of 10,000 common shares in several open-market trades. Reported weighted-average prices for these sales ranged from about $562.91 to $570.18 per share, based on multiple executions grouped into individual transaction lines.

How many United Therapeutics (UTHR) options did the CFO exercise, and at what strike prices?

He exercised stock options covering 10,000 shares of common stock. The filing shows 7,500 shares exercised at a strike price of $117.76 per share and 2,500 shares exercised at a strike price of $135.42 per share on May 18, 2026.

Was the United Therapeutics (UTHR) CFO’s share sale under a Rule 10b5-1 plan?

Yes. A footnote explains that the option exercises and subsequent share sales were executed pursuant to a Rule 10b5-1 trading plan. That plan was entered into by the reporting person on October 31, 2025, indicating the trades were pre-scheduled.

Does the United Therapeutics (UTHR) CFO still hold shares after these transactions?

Yes, the Form 4 indicates he continues to hold United Therapeutics common stock. Each transaction line lists a remaining share balance following the reported trades, showing that the reported activity did not fully liquidate his holdings.

What is meant by weighted average prices in the CFO’s United Therapeutics (UTHR) trades?

Several sale entries note they were executed in multiple trades within specified price ranges. The single price reported for each entry is the weighted average price, summarizing all individual executions for disclosure, with full details available upon request.